ArticleJournal of medical cases2023
Synchronous Occurrence of Triple-Negative Breast Cancer and Malignant Melanoma.
Article in Journal of medical cases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- A case report of synchronous bilateral breast cancer with distinct histological subtypes and favorable long-term survival.Frontiers in oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In people with cancer, multiple primary malignant neoplasms (MPMNs) are not unusual, and they may be caused by risk factors such as genetics, viral infection, smoking, environmental factors, or treatment-related variables. The frequency of MPMNs occurring in the same or separate organ systems is between 2% and 17%. The 5-year breast cancer survivors have been found to have around 3.6% chance of acquiring another neoplasm. In this case report, we present a very rare simultaneous occurrence of two highly malignant tumors - triple-negative breast cancer and cutaneous melanoma. We performed genetic tests for determining the link between both neoplasms. The patient was treated in an adjuvant setting with chemotherapy and immunotherapy with pembrolizumab. According to epidemiological studies, for primary cutaneous melanoma following breast cancer, the standardized incidence ratio (SIR) varied from 1.03 to 4.10, while for primary breast carcinoma following cutaneous melanoma, it varied from 1.16 to 5.13. A number of risk factors have been proven to increase the risk of a second primary malignancy. This case highlights the importance of risk factor assessment and thorough primary workup of each patient. It emphasizes the need for a personalized approach when treating synchronous neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.